<DOC>
	<DOCNO>NCT01171326</DOCNO>
	<brief_summary>Impetigo common , highly infectious skin disease cause bacterial infection characterize crust skin lesion . It common child , particularly child unhealthy living condition . In adult , may follow skin disorder . Impetigo cause primarily bacteria Streptococcus pyogenes and/or Staphylococcus aureus , also isolate impetigo lesion . This pilot phase II study evaluate tolerability safety monitor clinical efficacy Topical Minocycline Foam FXFM244 impetigo patient .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Topical Minocycline FXFM244 Impetigo Patients</brief_title>
	<detailed_description>A randomized , parallel-group , double ( Investigator , patient ) blind , comparative dose range find clinical trial . The study involve two treatment group . Eligible patient randomize receive either FXFM244 - 1 % , FXFM244 - 4 % , blind fashion . Patients treat twice daily 7 day . Following screening period baseline visit , study subject return day 3 , 7 14 . At visit , patient evaluate via lesion count , global assessment tolerability safety .</detailed_description>
	<mesh_term>Impetigo</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Patients clinical diagnosis pure impetigo , impetigo contagiosa , uncomplicated blistering impetigo Patients 2 year age old , general good health Patients less two lesion seven lesion , area 0.5x0.5cm . No known medical condition , Investigator 's opinion could interfere study participation Patient / Patient 's guardian ( case child ) willing able comply requirement protocol Patient / Patient 's guardian willing able give write informed consent prior participation study Presence skin disease near investigational area Immunosuppressed state serious systemic disease Signs and/or symptom systemic infection Presence skin infection/disorder amenable topical antibacterial treatment Presence secondarilyinfected animal/human bite Presence secondarily infect burn wound Topical systemic use medicinal product study ( oral topical antibiotic , oral topical corticosteroid immuno modulators ) ; drug , Investigators opinion could confound evaluation effect study drug Known suspect hypersensitivity Minocycline excipients study medication Participation investigational drug study use ( ) investigational drug ( ) within 30 day 5 halflives ( whichever longer ) prior randomization Patients previously enrolled/randomized study Use another investigational drug within 30 day prior entry study . Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>topical</keyword>
	<keyword>minocycline</keyword>
	<keyword>foam</keyword>
	<keyword>phase II</keyword>
	<keyword>impetigo</keyword>
</DOC>